Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
There are 2 manufactures for European Alunbrig: Takeda Austria GmbH St. Peter-Strasse 25 4020 Linz Austria Takeda Ireland Limited Bray Business Park Kilruddery Co. Wicklow A98 CD36 Ireland
Information about ALUNBRIG (Brigatinib)
ALUNBRIG (Brigatinib) is a medication primarily used in the treatment of lung cancer, specifically those with specific mutations.
ALUNBRIG is a prescription medicine used to treat adults with a certain type of abnormal anaplastic lymphoma kinase (ALK) gene that has spread to other parts of the body.
Product Highlights
ALUNBRIG (Brigatinib) is a targeted therapy designed to inhibit the activity of specific proteins involved in the growth of cancer cells, particularly in non-small cell lung cancer (NSCLC) that harbors ALK (anaplastic lymphoma kinase) mutations.
Your healthcare provider will start you on a low dose of ALUNBRIG (90 mg) for the first 7 days of treatment. If you tolerate this initial dose well, your healthcare provider may increase it after the first 7 days of treatment.
Key Ingredients
Brigatinib
Key Benefits
ALUNBRIG targets and inhibits ALK, a key driver mutation in some types of non-small cell lung cancer, thereby slowing down or stopping the growth of cancer cells.
Clinical trials have shown that ALUNBRIG can significantly improve progression-free survival compared to traditional chemotherapy in patients with ALK-positive NSCLC.
Direction For Use
Taken orally once daily with or without food.
Tablets should be swallowed whole with water and not chewed, crushed, or split.
Dosage adjustments may be necessary based on individual patient tolerability and side effects.
Recommended ALUNBRIG Dosage
Dosage
Dosage Reduction
First
Second
Second
90 mg once daily
60 mg once daily
Permanently Discontinue
N/A*
180 mg once daily
120 mg once daily
90 mg once daily
60 mg once daily
Safety Concern
Common side effects may include nausea, diarrhea, fatigue, cough, and elevated liver enzymes. Serious side effects such as interstitial lung disease and hypertension have been reported and require monitoring.
Regular monitoring of liver function tests, renal function, and pulmonary symptoms is recommended during treatment.
Potential interactions with other medications, particularly those metabolized by CYP3A4 enzymes, should be considered.
Avoid Taking ALUNBRIG (Brigatinib) If:
ALUNBRIG can cause fetal harm when administered to pregnant women. Therefore, it is contraindicated in pregnancy.
Patients with severe hepatic impairment should avoid ALUNBRIG due to the risk of increased exposure and potential toxicity.
Individuals who have had a severe hypersensitivity reaction to brigatinib or any of its components should not take ALUNBRIG.
